NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, News, & Analysis

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) issued its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.11. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.67 million. Dicerna Pharmaceuticals had a negative return on equity of 63.24% and a negative net margin of 1,418.01%. View Dicerna Pharmaceuticals' Earnings History.

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Dicerna Pharmaceuticals.

9 equities research analysts have issued 12 month target prices for Dicerna Pharmaceuticals' stock. Their forecasts range from $14.50 to $30.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $21.3125 in the next twelve months. This suggests a possible upside of 97.9% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Media coverage about DRNA stock has trended very positive this week, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a news impact score of 3.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Dicerna Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 5,979,289 shares, an increase of 75.9% from the December 14th total of 3,399,119 shares. Based on an average trading volume of 929,548 shares, the short-interest ratio is currently 6.4 days. Approximately 13.2% of the company's shares are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN) and Innoviva (INVA).

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $10.77.

Dicerna Pharmaceuticals has a market capitalization of $675.62 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]